South Korea’s biopharmaceutical sector has seen a surge in innovator drug licensing agreements, reaching a total deal value of $7.86bn in 2025 year-to-date (YTD), at a 113% increase from 2024, ...

The biopharma spinoff will advance the development of its five investigational therapies designed to treat autoimmune disease.

Despite being significantly lower than the 200% rate threatened by Trump, the deal is set to ramp up drug costs by billions.

Re-Vana Therapeutics has entered a partnership and licence agreement with Boehringer Ingelheim for the development of eye therapies.

Alfasigma is in discussions with the EMA and MHRA about Jyseleca for axSpA but has yet to reveal any plans for US submission.

The FDA has approved Ascendis Pharma’s Skytrofa (lonapegsomatropin-tcgd, developed as TransCon hGH) for the treatment of adults with GHD.

It has been a tumultuous two weeks for Sarepta; however, the FDA reauthorising US shipments of Elevidys will be a welcome development.

The European Commission (EC) has granted approval to Sanofi's Sarclisa in combination with a regimen of VRd for multiple myeloma.

Hengrui Pharma has signed an agreement with GSK for the development of up to 12 innovative medicines across several therapeutic areas.

The US biopharma has planted roots in the UK’s biotech cluster as it bets on synthetic rescue to unlock new treatments for rare diseases.

A new report examines why linked data is essential to advancing healthcare and improving outcomes for patients.